Research programme: anti-HAAH monoclonal antibodies - Sensei Biotherapeutics
Alternative Names: PAN 22; PAN-355; PAN-622Latest Information Update: 27 Dec 2022
At a glance
- Originator Massachusetts Institute of Technology
- Developer GBI; Massachusetts Institute of Technology; Sensei Biotherapeutics
- Class Monoclonal antibodies; Radiopharmaceutical diagnostics
- Mechanism of Action Aspartic acid 2-oxoglutarate-dependent dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Liver cancer
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for cancer (Diagnosis) in USA (Parenteral)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (Parenteral)
- 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics